- Home
- DMAC vs ABOS Comparison
DMAC vs ABOS Comparison
Compare DMAC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- ABOS
- Stock Information
- Founded
- DMAC 2000
- ABOS 1996
- Country
- DMAC United States
- ABOS United States
- Employees
- DMAC N/A
- ABOS N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- ABOS Health Care
- Exchange
- DMAC Nasdaq
- ABOS Nasdaq
- Market Cap
- DMAC 185.1M
- ABOS 171.8M
- IPO Year
- DMAC N/A
- ABOS 2021
- Fundamental
- Price
- DMAC $4.23
- ABOS $3.25
- Analyst Decision
- DMAC Strong Buy
- ABOS Strong Buy
- Analyst Count
- DMAC 3
- ABOS 4
- Target Price
- DMAC $7.00
- ABOS $9.00
- AVG Volume (30 Days)
- DMAC 34.2K
- ABOS 216.0K
- Earning Date
- DMAC 11-13-2024
- ABOS 11-15-2024
- Dividend Yield
- DMAC N/A
- ABOS N/A
- EPS Growth
- DMAC N/A
- ABOS N/A
- EPS
- DMAC N/A
- ABOS N/A
- Revenue
- DMAC N/A
- ABOS N/A
- Revenue This Year
- DMAC N/A
- ABOS N/A
- Revenue Next Year
- DMAC N/A
- ABOS N/A
- P/E Ratio
- DMAC N/A
- ABOS N/A
- Revenue Growth
- DMAC N/A
- ABOS N/A
- 52 Week Low
- DMAC $2.12
- ABOS $1.81
- 52 Week High
- DMAC $4.95
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- DMAC 45.24
- ABOS 66.05
- Support Level
- DMAC $4.14
- ABOS $2.85
- Resistance Level
- DMAC $4.48
- ABOS $3.30
- Average True Range (ATR)
- DMAC 0.18
- ABOS 0.22
- MACD
- DMAC -0.03
- ABOS 0.04
- Stochastic Oscillator
- DMAC 34.88
- ABOS 82.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.